Two versus three to four cycles of neoadjuvant immunochemotherapy for stage IB–IIIB non-small cell lung cancer: a real-world study
Three to four cycles of neoadjuvant immunochemotherapy can result in more tumor regression in IB-IIIB NSCLC. Extending the number of cycles to 3-4 cycles may be feasible and safe in IB-IIIB NSCLC.
Authors
- Linhai Zhu (ORCID: https://orcid.org/0000-0002-0433-5348)
- Hang Zhao (ORCID: https://orcid.org/0000-0001-6142-6193)
- Jinming Xu
- Wang Lv (ORCID: https://orcid.org/0009-0007-2014-0480)
- Jian Hu
- Jiayue Ye (ORCID: https://orcid.org/0000-0002-0371-0660)
- Yuhong Yang
- Xuhua Huang (ORCID: https://orcid.org/0000-0002-0022-2661)
- Jia-Cong Liu
Institutions
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Journal of Thoracic Disease
- Published
- 2025-02-01
- DOI
- https://doi.org/10.21037/jtd-2024-2256
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09